These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

207 related articles for article (PubMed ID: 35428720)

  • 21. Sustained benefits of infliximab therapy for dermatologic and articular manifestations of psoriatic arthritis: results from the infliximab multinational psoriatic arthritis controlled trial (IMPACT).
    Antoni CE; Kavanaugh A; Kirkham B; Tutuncu Z; Burmester GR; Schneider U; Furst DE; Molitor J; Keystone E; Gladman D; Manger B; Wassenberg S; Weier R; Wallace DJ; Weisman MH; Kalden JR; Smolen J
    Arthritis Rheum; 2005 Apr; 52(4):1227-36. PubMed ID: 15818699
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Comparison of disease activity index for psoriatic arthritis (DAPSA) and minimal disease activity (MDA) targets for patients with psoriatic arthritis: A post hoc analysis of data from phase 3 tofacitinib studies.
    Schneeberger EE; Citera G; Nash P; Smolen JS; Mease PJ; Soriano ER; Helling C; Szumski AE; Mundayat R; de León DP
    Semin Arthritis Rheum; 2023 Feb; 58():152134. PubMed ID: 36476498
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Long-Term Efficacy and Safety of Guselkumab, a Monoclonal Antibody Specific to the p19 Subunit of Interleukin-23, Through Two Years: Results From a Phase III, Randomized, Double-Blind, Placebo-Controlled Study Conducted in Biologic-Naive Patients With Active Psoriatic Arthritis.
    McInnes IB; Rahman P; Gottlieb AB; Hsia EC; Kollmeier AP; Xu XL; Jiang Y; Sheng S; Shawi M; Chakravarty SD; van der Heijde D; Mease PJ
    Arthritis Rheumatol; 2022 Mar; 74(3):475-485. PubMed ID: 34719872
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Oral apremilast in the treatment of active psoriatic arthritis: results of a multicenter, randomized, double-blind, placebo-controlled study.
    Schett G; Wollenhaupt J; Papp K; Joos R; Rodrigues JF; Vessey AR; Hu C; Stevens R; de Vlam KL
    Arthritis Rheum; 2012 Oct; 64(10):3156-67. PubMed ID: 22806399
    [TBL] [Abstract][Full Text] [Related]  

  • 25. What Should Be the Primary Target of "Treat to Target" in Psoriatic Arthritis?
    Coates LC; Lubrano E; Perrotta FM; Emery P; Conaghan PG; Helliwell PS
    J Rheumatol; 2019 Jan; 46(1):38-42. PubMed ID: 30219765
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Apremilast: A Review in Psoriasis and Psoriatic Arthritis.
    Keating GM
    Drugs; 2017 Mar; 77(4):459-472. PubMed ID: 28213862
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Longterm (52-week) results of a phase III randomized, controlled trial of apremilast in patients with psoriatic arthritis.
    Kavanaugh A; Mease PJ; Gomez-Reino JJ; Adebajo AO; Wollenhaupt J; Gladman DD; Hochfeld M; Teng LL; Schett G; Lespessailles E; Hall S
    J Rheumatol; 2015 Mar; 42(3):479-88. PubMed ID: 25593233
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Efficacy of tofacitinib on enthesitis in patients with active psoriatic arthritis: analysis of pooled data from two phase 3 studies.
    Mease PJ; Orbai AM; FitzGerald O; Bedaiwi M; Dona L Fleishaker ; Mundayat R; Young P; Helliwell PS
    Arthritis Res Ther; 2023 Aug; 25(1):153. PubMed ID: 37608391
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Apremilast and its role in psoriatic arthritis.
    Sandhu VK; Eder L; Yeung J
    G Ital Dermatol Venereol; 2020 Aug; 155(4):386-399. PubMed ID: 33050680
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Residual Disease Burden in Patients With Axial Spondyloarthritis and Psoriatic Arthritis Despite Low Disease Activity States in a Multiethnic Asian Population.
    Liu V; Fong W; Kwan YH; Leung YY
    J Rheumatol; 2021 May; 48(5):677-684. PubMed ID: 33132217
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Ixekizumab and complete resolution of enthesitis and dactylitis: integrated analysis of two phase 3 randomized trials in psoriatic arthritis.
    Gladman DD; Orbai AM; Klitz U; Wei JC; Gallo G; Birt J; Rathmann S; Shrom D; Marzo-Ortega H
    Arthritis Res Ther; 2019 Jan; 21(1):38. PubMed ID: 30696483
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Gender-related differences in disease activity and clinical features in patients with peripheral psoriatic arthritis: A multi-center study.
    Duruöz MT; Gezer HH; Nas K; Kılıç E; Sargın B; Kasman SA; Alkan H; Şahin N; Cengiz G; Cüzdan N; Gezer İA; Keskin D; Mülkoğlu C; Reşorlu H; Ataman Ş; Bal A; Küçükakkaş O; Yurdakul OV; Melikoğlu MA; Baykul M; Ayhan FF; Bodur H; Çalış M; Çapkın E; Devrimsel G; Gök K; Hizmetli S; Kamanlı A; Keskin Y; Ecesoy H; Kutluk Ö; Şen N; Şendur ÖF; Tekeoğlu İ; Tolu S; Toprak M; Tuncer T
    Joint Bone Spine; 2021 Jul; 88(4):105177. PubMed ID: 33771757
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Dactylitis is an indicator of a more severe phenotype independently associated with greater SJC, CRP, ultrasound synovitis and erosive damage in DMARD-naive early psoriatic arthritis.
    Dubash S; Alabas OA; Michelena X; Garcia-Montoya L; Wakefield RJ; Helliwell PS; Emery P; McGonagle DG; Tan AL; Marzo-Ortega H
    Ann Rheum Dis; 2022 Apr; 81(4):490-495. PubMed ID: 34893470
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Comparison of Composite Measure Remission Targets in Psoriatic Arthritis.
    Farkas F; Ikumi N; Elmamoun M; Szentpetery A; FitzGerald O
    J Rheumatol; 2021 Aug; 48(8):1272-1278. PubMed ID: 33722944
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Secukinumab provides sustained PASDAS-defined remission in psoriatic arthritis and improves health-related quality of life in patients achieving remission: 2-year results from the phase III FUTURE 2 study.
    Coates LC; Gladman DD; Nash P; FitzGerald O; Kavanaugh A; Kvien TK; Gossec L; Strand V; Rasouliyan L; Pricop L; Ding K; Jugl SM; Gaillez C;
    Arthritis Res Ther; 2018 Dec; 20(1):272. PubMed ID: 30526678
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Impact of clinical domains other than arthritis on composite outcomes in psoriatic arthritis: comparison of treatment effects in the SEAM-PsA trial.
    Helliwell PS; Mease PJ; Kavanaugh A; Coates LC; Ogdie A; Deodhar A; Strand V; Kricorian G; Liu LXH; Collier D; Gladman DD
    RMD Open; 2022 Jul; 8(2):. PubMed ID: 35863864
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The pharmacodynamic impact of apremilast, an oral phosphodiesterase 4 inhibitor, on circulating levels of inflammatory biomarkers in patients with psoriatic arthritis: substudy results from a phase III, randomized, placebo-controlled trial (PALACE 1).
    Schafer PH; Chen P; Fang L; Wang A; Chopra R
    J Immunol Res; 2015; 2015():906349. PubMed ID: 25973439
    [TBL] [Abstract][Full Text] [Related]  

  • 38. An indirect comparison and cost per responder analysis of adalimumab, methotrexate and apremilast in the treatment of methotrexate-naïve patients with psoriatic arthritis.
    Betts KA; Griffith J; Friedman A; Zhou ZY; Signorovitch JE; Ganguli A
    Curr Med Res Opin; 2016; 32(4):721-9. PubMed ID: 26743448
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Real-world apremilast use in biologic-naïve psoriatic arthritis patients. Data from Spanish clinical practice.
    Gratacós-Masmitja J; Beltrán Catalán E; Álvarez Vega JL; Urruticoechea-Arana A; Fito C; Maceiras F; Belzunegui Otano JM; Fernández Melón J; Chamizo Carmona E; Abad Hernández MÁ; Ros Vilamajó I; Castro Oreiro S; Pascual Alfonso E; Torre Alonso JC;
    Reumatol Clin (Engl Ed); 2024 Jan; 20(1):24-31. PubMed ID: 38233009
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Ideal target for psoriatic arthritis? Comparison of remission and low disease activity states in a real-life cohort.
    van Mens LJJ; van de Sande MGH; van Kuijk AWR; Baeten D; Coates LC
    Ann Rheum Dis; 2018 Feb; 77(2):251-257. PubMed ID: 29080861
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.